[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"left-ventricular-lv-systolic-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:left-ventricular-lv-systolic-dysfunction":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,83,113,139,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100638696","pascal-precision-gdmt-registry-100638696",false,"NCT07578129","PASCAL Precision-GDMT Registry","Improvement in Guideline-Directed Medical Therapy After Tricuspid Transcatheter Edge-to-Edge Repair in Participants With Reduced Left Ventricular Function","PASCAL","Inclusion Criteria:\n\n* Participants of age ≥ 18 years\n* ≥ severe tricuspid regurgitation\n* LVEF \\\u003C 50%\n* Written informed consent of the patient or her\u002Fhis legal representative\n* Patient understands the purpose, the potential risks as well as benefits of the trial and is willing to participate in all parts of the follow-up\n* Planned follow-up within a dedicated heart failure clinic as part of routine care.\n\nExclusion Criteria:\n\n* Anatomy unsuitable for TEER as determined by local heart team\n* severe mitral regurgitation (defined as an EROA\\>40 mm2) treated (surgically or percutaneously) less than 3 months prior\n* severe left ventricular dysfunction (defined as an LVEF \\\u003C20%)\n* systolic pulmonary artery pressure \\>70 mmHg (right heart catheterization)\n* prior tricuspid valve intervention\n* severe leaflet degeneration or tricuspid valve anatomy precluding successful device placement\n* primary tricuspid valve disease\n* COPD requiring home oxygen therapy\n* active endocarditis, or recent episode within 4 weeks of discontinuation of antibiotic therapy\n* participants with unstable hemodynamic condition\n* significant co-morbidities resulting in an expected less than 12-month life expectancy\n* The presence of other anatomic or comorbid conditions or other medical, social or psychological conditions that in the investigators' opinion could limit the subject's ability to participate in the clinical study and its follow-up.\n* Participants under judicial protection, guardianship or curatorship or if they are deprived of their liberty by judicial or administrative decision\n* Participation in another trial, which would lead to deviations in the preparation or performance of the intervention or the post-implantation management from this protocol","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","12 Months","OBSERVATIONAL","The goal of this observational study is to demonstrate that successful tricuspid valve repair with the PASCAL Precision System in participants with at least severe tricuspid insufficiency and left ventricular dysfunction will be associated with an improvement in up-titration of guideline-directed medical therapy (GDMT). The main question it aims to answer is:\n\nDoes the tricuspid insufficiency repair with the Pascal Precision System increases the dose of the medications used for heart failure therapy in the study population 12 months after tricuspid repair, as compared to the dose taken at baseline.\n\nParticipants undergoing tricuspid repair and fulfilling all inclusion\u002Fexclusion criteria will be asked to answer heart failure assessment as well as quality of life questionnaires at baseline and at 12 months post intervention. Medication monitoring will be performed throughout the study.",[26,27,28,29,30,31],"Tricuspid Insufficiency","Tricuspid Regurgitation (TR)","Left Ventricular Cardiac Dysfunction","Left Ventricular (LV) Systolic Dysfunction","Left Ventricular Dysfunction","Left Ventricular Ejection Fraction",[33,34,35,36,37,38],"T-TEER","Severe Tricuspid regurgitation","left ventricular dysfunction","GDMT score","NHYA","KCCQ","NOT_YET_RECRUITING","2026-05-11",{"date":42,"type":43},"2026-05-13","ACTUAL",{"date":45,"type":21},"2026-08-01",{"date":47,"type":21},"2027-08-31",{"name":49,"class":50},"Ceric Sàrl","INDUSTRY",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100586795","performance-of-the-cardiac-microcurrent-c-mic-system-with-a-less-invasively-placed-left-ventricular-lead-100586795","NCT06920030","Performance of the Cardiac Microcurrent (C-MIC) System With a Less Invasively Placed Left Ventricular Lead","Pilot Study to Investigate the Performance of the Cardiac Microcurrent (C-MIC) System With a Less Invasively Placed Left Ventricular Lead","Inclusion Criteria Idiopathic Dilated Cardiomyopathy with HFrEF:\n\n1. Patients with idiopathic dilated cardiomyopathy who have systolic left ventricular dysfunction despite adequate therapy of heart failure (NYHA III - IV).\n2. Patients who have a baseline left ventricular ejection fraction of ≥25% and ≤35% assessed by corelab.\n\nInclusion Criteria Non-Ischaemic Cardiomyopathy with HFmrEF:\n\n1. Patients with non-ischemic cardiomyopathy with mildly reduced left ventricular ejection fraction despite adequate therapy of heart failure (NYHA III - IV).\n2. Patients who have a baseline left ventricular ejection fraction of \\>40% and \\\u003C50% assessed by corelab.\n\n   Inclusion Criteria for all Patients:\n3. Patients with symptomatic chronic heart failure for more than 1 year and less than 5 years at screening based on the date of diagnosis.\n4. Female and male patients aged ≥18 years - 75 years.\n5. Patient who understands the nature of the procedure and on-going device therapy. Patient is informed about their participation in a chronic clinical trial and about the intended treatment period of 6 months which is derived by the fact that according to current knowledge microcurrent treatment exceeding 6 months will not have additional favorable effects which means it will not further improve cardiac function. Furthermore, the patient is informed about the possibility of device explantation, informed regarding possible risks and is able to give written informed consent prior to any procedures and is considered willing and able to adhere to the study regimen and to return for all follow-up visits.\n6. Patients receiving appropriate, stable guideline directed medical therapy for heart failure at least for the 3 months prior to screening. Stable is defined as no more than a 50% increase or 50% decrease in dose. If the patient is intolerant of guideline recommended doses of heart failure medication, documented evidence must be available.\n\n   Guideline directed medical therapy includes for:\n\n   • Patients with HFrEF:\n\n   \\- Angiotensin-converting enzyme inhibitor (ACE-I) or\n\n   \\- Angiotensin receptor-neprilysin inhibitor (ARNI)\n\n   \\- Beta-blocker\n\n   \\- Mineralocorticoid receptor antagonist (MRA)\n\n   \\- Dapagliflozin\u002FEmpagliflozin inhibitor (SGLT2i)\n   * Patients with HFmrEF - Diuretics (if symptomatic)\n\n     * Dapagliflozin\u002FEmpagliflozin inhibitor (SGLT2i)\n7. Patients who can perform a non-assisted 6-minute walk test.\n8. Patients must have a body mass index within the range of 20 - 36 kg\u002Fm².\n9. Informed consent in writing obtained from patient.\n\nExclusion Criteria:\n\nPatients who are not likely to experience improvement of their chronic heart failure by the microcurrent therapy, because the causes of the disease cannot be influenced even if the patients fulfill the indication for use of the device or if the therapy with the C-MIC System is not possible or might be associated with unknown risks:\n\n1. Patients who have a potentially correctible cause of heart failure, such as valvular heart disease or congenital heart disease.\n2. Patients with an indication for a CRT system according to current guidelines.\n3. Patients who have been hospitalized for heart failure which required the use of inotropic support within 30 days before screening.\n4. Patients with systolic blood pressure above 150 mmHg and diastolic blood pressure above 90 mmHg despite optimal antihypertensive medical treatment.\n5. Patients with hemoglobin blood level \\\u003C 12 g\u002Fdl in male and \\\u003C 10 g\u002Fdl in female patients.\n6. Patients with primary pulmonary hypertension\n7. Patients who have genetic connective tissue disease (for example Marfan syndrome).\n8. Patients with a prosthetic tricuspid valve.\n9. Patients in whom access for implantation of the leads cannot be obtained (i.e. known venous occlusion, post radiation therapy).\n10. Patient with other features (i.e. thorax deformity) that in the eyes of the investigator make the straightforward placement of the device seem unlikely.\n11. Patients with a pacemaker, an ICD system, a CRT system or with a CCM system.\n12. Current pregnancy or\n13. Breastfeeding\u002Flactating women\n14. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception (e.g. intrauterine device, oral contraceptives, barrier methods, or other contraception deemed adequate by the investigator) 2 months before and until 1 month after C-MIC therapy.\n\n    Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 2 months before screening.\n15. Patients whose exercise tolerance is limited by a condition other than heart failure (e.g. chronic obstructive pulmonary disease, peripheral vascular 16.\n\nPatients on immunosuppressive therapy. 17.Patie nts with present malignancy. 18. Patients with an active infection considered by the investigator to be unsafe for the patient's participation in the study.\n\n19\\. Patients with renal dysfunction (i.e., estimated glomerular filtration rate \\\u003C45 mL\u002Fmin \u002F1,73 m²). Use the \"CKD-EPI Creatinine Equation (2021)\" as found on https:\u002F\u002Fwww.kidney.org\u002Fprofessionals\u002Fgfr\\_calculator.\n\n20\\. Patients with history or presence of relevant liver diseases or hepatic dysfunction as indicated by abnormal liver function tests at screening and baseline: ALT (SGPT), AST (SGOT), γ-GT, alkaline, phosphatase and serum bilirubin \\> 2 × upper limit of normal (ULN). Increase of these liver enzymes caused by cardiac disorders in the absence of other possible causes of liver damage are not meant by this.\n\n21\\. Patients with a history of drug or alcohol abuse within the 12 months prior to screening.\n\n22\\. Patients who, in the opinion of the Principal Investigator, are unlikely to comply with the protocol requirements, instructions and trial related restrictions, e.g., uncooperative attitude, inability to return for follow-up visits, psychological illness, and improbability of completing the trial.\n\n23\\. Participation in any study of an investigational device or drug within 90 days prior to planned study.\n\n24\\. Vulnerable Patients (e.g. patients requiring a legal representative, patients kept in detention, any service within the army, and employees of the sponsor or at an investigator site).\n\n25\\. Patients who are not able to avoid the following areas (i.e. due to work):\n\n* Areas with strong magnetic fields\n* Areas with strong external electrical influences\n* Areas with a warning notice \"Access prohibited for pacemaker patients\" or similar.\n* Areas with high temperatures","75 Years",{"count":60,"type":21},22,"INTERVENTIONAL",[63],"NA","Patients with idiopathic dilated cardiomyopathy in heart failure (NYHA class III - IV) with a baseline left ventricular ejection fraction between ≥25% and ≤35%, and patients with non-ischemic cardiomyopathy in heart failure (NYHA class III-IV) with a baseline left ventricular ejection fraction \\>40% and \\\u003C50% despite guideline-directed medical therapy, will receive C-MIC treatment in addition to optimal medical management.\n\nThe device can be implanted without the need for open-heart surgery. Patients are assigned to one of two groups according to the indications under investigation. At the end of the study after 6 months, the C-MIC System will be turned off. The primary endpoint of the study is the absolute change in left ventricular ejection fraction after 6 months of treatment.",[66,29,67],"Idiopathic Cardiomyopathy","Non-ischemic Cardiomyopathy",[69,70,71],"dilated cardiomyopathy","heart failure","non-ischemic cardiomyopathy","RECRUITING","2026-03-16",{"date":75,"type":43},"2026-03-18",{"date":77,"type":43},"2025-04-09",{"date":79,"type":21},"2027-04",{"name":81,"class":50},"Berlin Heals GmbH",4,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":61,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":112},"100612024","ketamine-lidocaine-versus-ketamine-fentanyl-for-induction-of-anesthesia-in-patients-with-left-ventricular-systolic-dysfunction-undergoing-elective-coronary-artery-bypass-100612024","NCT07248202","Ketamine-lidocaine Versus Ketamine-fentanyl for Induction of Anesthesia in Patients With Left Ventricular Systolic Dysfunction Undergoing Elective Coronary Artery Bypass","A Comparison Between the Effect of Ketamine-lidocaine Versus Ketamine-fentanyl for Induction of Anesthesia on Cerebral Perfusion Guided by Near Infra-red Spectroscopy in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction Undergoing Elective Coronary Artery Bypass Graft Surgery: (A Randomized Controlled Study)","Inclusion Criteria:\n\n* patients with coronary artery disease\n* with moderate to severe left ventricular dysfunction (ejection fraction \\\u003C 40%),\n* scheduled for elective CABG surgery\n\nExclusion Criteria:\n\n* associated chronic stroke, TIA , carotid occlusive disease( due to abnormal vasomotor activity), patients with known neurological impairment (cerebral infarction , dementia ), significant carotid artery stenosis ,\n* valvular heart disease,\n* persistent arrhythmias,\n* congestive cardiac failure,\n* on mechanical ventilation,\n* intra-aortic balloon pump,\n* emergency surgery,\n* and those with known allergy to any of the study's drugs,\n* severe systemic non-cardiac disease and\n* patients with baseline NIRS reading \\\u003C 60%\n* Patients with dementia or visual or auditory impairment","21 Years",{"count":92,"type":21},40,[63],"This study compares ketamine\u002Ffentanyl versus ketamine\u002Flidocaine in term of their impact on cerebral perfusion during CABG. No prior data address these effects, and the goal is to identify the induction regimen that better preserves cerebral oxygenation.",[96,29,97,98,99,100,101],"Coronary Artery Disease (CAD)","Induction Anesthesia","Coronary Bypass Graft Surgery","Ketamine","Fentanyl","Lidocaine","2026-03-15",{"date":104,"type":43},"2026-03-17",{"date":106,"type":43},"2025-12-01",{"date":108,"type":21},"2026-07",{"name":110,"class":111},"Cairo University","OTHER",1,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":119,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":61,"phases":122,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":112},"100620238","ai-enabled-electrocardiogram-guided-guideline-directed-medical-therapy-on-incident-left-ventricular-dysfunction-a-target-trial-emulation-study-100620238","NCT07355023","AI-Enabled Electrocardiogram-Guided Guideline-Directed Medical Therapy on Incident Left Ventricular Dysfunction: A Target Trial Emulation Study","Inclusion Criteria:\n\n* With an ECG followed by an echocardiogram within a 90-day interval\n* With preserved left ventricular ejection fraction (LVEF ≥ 50%)\n\nExclusion Criteria:\n\n* missing essential variables or ECG lead data\n* any prior LVEF \\\u003C 50%\n* loss to follow-up or death during the 90-day assessment window",true,{"count":121,"type":21},5000,[63],"This multicenter retrospective study evaluates whether artificial intelligence-enabled electrocardiography (AI-ECG) can identify individuals at high risk for left ventricular dysfunction and whether targeted guideline-directed medical therapy can mitigate subsequent risk. Using a large multicenter cohort of patients with preserved left ventricular systolic function, the investigators applied an AI-ECG-based risk stratification approach and emulated a target trial to examine the association between guideline-directed therapies and the risk of incident left ventricular functional decline.",[29],[126,127,128,129],"Artificial intelligence","Electrocardiogram","Deep learning","Left ventricular dysfunction","2026-01-12",{"date":132,"type":43},"2026-01-21",{"date":134,"type":21},"2026-01-01",{"date":136,"type":21},"2026-01-15",{"name":138,"class":111},"Tri-Service General Hospital",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":61,"phases":149,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100470880","hybrid-ablation-of-atrial-fibrillation-in-heart-failure-100470880","NCT05411614","Hybrid Ablation of Atrial Fibrillation in Heart Failure","A Randomised Controlled Trial Comparing Convergent Hybrid Ablation to Catheter Ablation in Patients With Persistent Atrial Fibrillation and Heart Failure","HALT AF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Persistent or Long-standing Persistent AF\n* Dilated left atrium (at least moderately dilated)\n* Suitable for either procedure\n* LVEF \\\u003C 50%\n\nExclusion Criteria:\n\n* Not yet optimised from a medical or lifestyle perspective for AF or heart failure\n* Unable to provide written consent\n* Previous open-heart surgery\n* Active infection, oesophageal ulcer stricture or oesophageal varices\n* Prior catheter ablation of atrial fibrillation (prior ablation for atrial flutter \u002F supraventricular tachycardia or ventricular arrhythmia acceptable)\n* Contraindication to anticoagulation, or active thrombus in the left atrium despite therapeutic anticoagulation\n* Severe valvular heart disease\n* Unstable coronary artery disease\n* Uncontrolled ventricular arrhythmia\n* Heart attack or stroke within the last 90 days\n* Pregnant, breastfeeding, or women of childbearing age who plan to get pregnant within six months\n* Severe concomitant condition or presence of an implanted device that would preclude the patient from undergoing trial procedures",{"count":148,"type":21},120,[63],"A randomised controlled trial to assess the efficacy of staged hybrid ablation when compared with standard catheter ablation in patients with non-paroxysmal atrial fibrillation (AF) and Heart Failure",[152,153,154,155,156,29],"Persistent Atrial Fibrillation","Atrial Fibrillation, Persistent","Atrial Arrhythmia","Atrial Fibrillation","Heart Failure","2025-11-23",{"date":159,"type":43},"2025-11-28",{"date":161,"type":43},"2022-06-25",{"date":163,"type":21},"2027-10",{"name":165,"class":111},"St. George's Hospital, London",7,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":119,"sex":17,"minAge":174,"maxAge":4,"enrollmentInfo":175,"targetDuration":177,"studyType":23,"phases":4,"briefSummary":178,"conditions":179,"keywords":182,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":112},"100578455","ai-based-prediction-of-cardiac-function-using-echocardiography-and-body-composition-data-echo-fit-study-100578455","NCT06811519","AI-based Prediction of Cardiac Function Using Echocardiography and Body Composition Data (ECHO-FIT Study)","ECHO-FIT","Inclusion Criteria:\n\n* Aged 20 years or older.\n* Undergoing a standard echocardiographic examination.\n* Providing consent to undergo body composition analysis.\n* Signing the informed consent form to voluntarily participate in the study.\n\nExclusion Criteria:\n\n* Having a physical or mental condition that makes it impossible to conduct an echocardiogram or perform body composition analysis.\n* Deemed inappropriate for study participation by the researcher (e.g., unable to cooperate).","20 Years",{"count":176,"type":21},2000,"1 Year","This prospective observational study (ECHO-FIT Study) aims to develop and validate a predictive model for cardiac function, particularly left ventricular ejection fraction (LVEF), by integrating echocardiographic measurements with body composition data obtained from the QCCUNIQ BC 720 device.\n\nThe study plans to enroll 2,000 adult participants, comprising 1,000 individuals with normal LVEF (≥50%) and 1,000 with heart failure (LVEF \\\u003C50%), all of whom will undergo standard-of-care echocardiography and body composition analysis.\n\nBy analyzing the relationships between key echocardiographic parameters (such as LVEF and diastolic function) and body composition measures (including fat mass, skeletal muscle mass, and total body water), we will develop a non-invasive prediction model capable of identifying individuals at higher risk of cardiac dysfunction.\n\nThis innovative approach has the potential to enhance early detection and personalized management of heart failure, reduce dependence on resource-intensive diagnostic procedures, and ultimately improve patient outcomes.",[156,29,180,181],"Body Composition Measurement","Artificial Intelligence (AI)",[70,183],"left ventricular systolic dysfunction","2025-03-01",{"date":186,"type":43},"2025-03-04",{"date":188,"type":43},"2025-02-24",{"date":190,"type":21},"2028-12-31",{"name":192,"class":111},"Yonsei University"]